Pharmaceuticals
JIXING ANNOUNCES RECEIPT OF BREAKTHROUGH THERAPY DESIGNATION FOR AFICAMTEN IN CHINA
SHANGHAI, Feb. 16, 2022 /PRNewswire/ -- Ji Xing Pharmaceuticals Limited (JIXING), a clinical-stage biopharmaceutical company committed to bringing innovative medicines to underserved Chinese patients with serious and life-threatening diseases, today announced that the Center for Drug Evaluation ...
2022-02-16 18:06
2591
Sirnaomics Receives Safe to Proceed Letter for U.S. FDA Investigational New Drug Application for Systemic RNAi Therapeutic STP707 in Primary Sclerosing Cholangitis (PSC)
HONG KONG, Feb. 16, 2022 /PRNewswire/ -- Sirnaomics Ltd. (the "Company" or " Sirnaomics", stock code: 2257.HK), a leading biopharmaceutical company in discovery and development of RNAi therapeutics, announced that they have received the "safe to proceed" letter from the U.S. Food and Drug Adminis...
2022-02-16 17:04
3142
NIBIOHN, Shionogi Discover Host Immune-dependent Novel Anti-coronavirus Antibody
OSAKA, Japan, Feb. 16, 2022 /PRNewswire/ -- The National Institutes of Biomedical Innovation, Health and Nutrition (NIBIOHN;Ibaraki-shi, Osaka; Director-general:Yoshihiro Yoneda), in partnership with Shionogi & Co., Ltd. (Chuo-ku,Osaka; President and CEO: Isao Teshirogi), has successfully identif...
2022-02-16 14:00
2467
A Breakthrough in Probiotic Therapy - Personalized Probiotics (Dispensing) Machine for a Balanced and Enhanced Immune System
BANGKOK, Feb. 16, 2022 /PRNewswire/ -- MED-CU has invented a Personalized
Probiotics (Dispensing) Machine to deliver live microorganisms that have health
benefits to treat patients with unclear health problems and those with
microbial imbalances or "dysbiosis".
2022-02-16 10:00
2362
Travecta Therapeutics Appoints Leading Experts to Expand its Scientific Advisory Leadership Team
PRINCETON, N.J. and SINGAPORE, Feb. 15, 2022 /PRNewswire/ -- Travecta Therapeutics, Pte Ltd., a preclinical stage biopharmaceutical company pioneering a portfolio of product candidates engineered to cross the blood-brain-barrier, today announced significant expansion of the Scientific Advisory B...
2022-02-15 21:00
1579
Travecta Therapeutics Appoints Leading Experts to Expand its Scientific Advisory Leadership Team
PRINCETON, N.J. and SINGAPORE, Feb. 15, 2022 /PRNewswire/ -- Travecta Therapeutics, Pte Ltd., a preclinical stage biopharmaceutical company pioneering a portfolio of product candidates engineered to cross the blood-brain-barrier, today announced significant expansion of the Scientific Advisory B...
2022-02-15 21:00
1988
HPG: New Breakthrough in Virus Inactivation with Green Tea Catechin (EGCg)
TOKYO, Feb. 15, 2022 /PRNewswire/ -- HPG Co., Ltd. (Chuo-ku, Tokyo) has successfully developed a water-soluble formulation technology of highly concentrated catechin EGCg (Epigallocatechin gallate) with excellent storage stability and initiated procedures for a patent application for the technol...
2022-02-15 16:00
2542
AffaMed Therapeutics Announces IND Clearance by US FDA for AM712 - a Novel Bispecific Biologic for the Treatment of Retinal Vascular Diseases
SHANGHAI, Feb. 15, 2022 /PRNewswire/ -- AffaMed Therapeutics ("AffaMed"), a global clinical stage biotechnology company dedicated to developing and commercializing transformative pharmaceutical, digital and surgical products, today announced that the United States Food and Drug Administration (FD...
2022-02-15 15:05
1374
G-NiiB probiotics - world's first microbiome-based immunity formulas now available at IMI
HONG KONG, Feb. 15, 2022 /PRNewswire/ -- IMI - Integrated Medicine Institute, Asia's largest natural health clinic, is pleased to announce the availability of G-NiiB Immunity Proand G-NiiB Immunity Plus probiotic formulas designed to tackle gut bacterial imbalances (dysbiosis) - a widespread healt...
2022-02-15 09:30
2990
Shanghai Public Health Clinical Center Initiated Functional Cure Study of Anti-PD-L1 Antibody ASC22 (Envafolimab) in Combination With Chidamide in HIV-Infected Patients
HANGZHOU, China and SHAOXING, China, Feb. 14, 2022 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX: 1672) today announces that Shanghai Public Health Clinical Center initiated functional cure study of anti-PD-L1 antibody ASC22 (Envafolimab) in combination with Chidamide in patients infected by human ...
2022-02-14 17:34
3594
U.S. FDA Grants Orphan Drug Designation to BCMA CAR-T Cell Therapy Co-Developed by IASO Bio and Innovent
NANJING, China and SHANGHAI and SAN JOSE, Calif., Feb. 13, 2022 /PRNewswire/ -- IASO Biotherapeutics ("IASO Bio"), a clinical-stage biopharmaceutical company engaged in discovering, developing, and manufacturing innovative cell therapies and antibody products, and Innovent Biologics, Inc. ("Innov...
2022-02-14 08:25
2563
U.S. FDA Grants Orphan Drug Designation to BCMA CAR-T Cell Therapy Co-Developed by Innovent and IASO Bio
SAN FRANCISCO and SUZHOU, China, Feb. 14, 2022 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent", HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of cancer, metabolic, autoimmune and other major disea...
2022-02-14 08:00
3927
Ascletis Announces Submission of Marketing Authorization Applications for Ritonavir in Multiple European Countries
HANGZHOU, China and SHAOXING, China, Feb. 13, 2022 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX: 1672) today announces that it has submitted marketing authorization applications for ritonavir (100 mg film-coated tablet) inGermany, France, Ireland and United Kingdom through its agent in Europe. It i...
2022-02-13 18:30
4141
Qilian International Holding Group Limited Reports Fiscal Year 2021 Financial Results
JIUQUAN, China, Feb. 11, 2022 /PRNewswire/ -- Qilian International Holding Group Limited (Nasdaq: QLI) (the "Company", "Qilian International", "we", "our" or "us"), aChina-based pharmaceutical and chemical products manufacturer, today announced its unaudited financial results for the fiscal year ...
2022-02-12 06:05
6277
Kintor Pharma Announces First Patient Dosing in China in Phase III Clinical Trial of Proxalutamide for the Treatment of COVID-19 Outpatients
SUZHOU, China, Feb. 11, 2022 /PRNewswire/ -- Kintor Pharmaceutical Limited ("Kintor Pharma," HKEX: 9939), a clinical-stage biotechnology company developing innovative small molecules and biological therapeutics, today announced the enrollment and dosing of first patient inChina in its multi-regi...
2022-02-11 20:40
4204
Novavax Announces Positive Results of COVID-19 Vaccine in Pediatric Population of PREVENT-19 Phase 3 Clinical Trial
- PREVENT-19 pediatric expansion in adolescents aged 12 through 17 achieved primary effectiveness endpoint demonstrating comparability to adult population - Trial demonstrated 82% clinical efficacy against Delta variant - Immune responses were about two-to-three-fold higher in adolescents than in...
2022-02-11 10:45
3574
FDA Advisory Committee Votes to Recommend Additional Data for Sintilimab Submission
SAN FRANCISCO, and SUZHOU, China, Feb. 11, 2022 /PRNewswire/ -- The U.S. Food and Drug Administration (FDA) held a public Oncology Drug Advisory Committee (ODAC) for sintilimab, which is under review for the first-line treatment of people with non-squamous non-small cell lung cancer (nsqNSCLC) ba...
2022-02-11 10:44
3600
Alphamab Oncology Announced IND Approval of PD-L1/OX40 Bispecific Antibody KN052
SUZHOU, China, Feb. 11, 2022 /PRNewswire/ -- Alphamab Oncology (stock code: 9966.HK) announced, that the company received the IND approval from the National Medical Products Administration (NMPA) for the company's innovative bispecific antibody KN052 (PD-L1/OX40 bispecific antibody) to initiate c...
2022-02-11 09:31
3460
Ucello Therapeutics Completes US$25 Million Series A Financing
SAN DIEGO, Calif. and CHENGDU, China, Feb. 10, 2022 /PRNewswire/ -- Ucello Therapeutics ("Ucello"), a biotechnology company developing universal CAR-T therapies, announced the successful completion of aUS$25 million Series A financing. The funding round was led by Matrix Partners China, alon...
2022-02-11 02:16
1986
Seegene Signs Supply Deal to Deliver 4 million COVID-19 Tests to Brazil
SEOUL, South Korea, Feb. 10, 2022 /PRNewswire/ -- Seegene Inc. (KQ 096530), South Korea's leading molecular diagnostic company, today announced that it has signed a supply deal with the Ministry of Health ofBrazil to deliver four million COVID-19 tests. Since January 2022, Brazil has battled a...
2022-02-10 20:00
2430
Week's Top Stories
Most Reposted
ASTON MARTIN ARAMCO FORMULA ONE® TEAM ANNOUNCE PEPPERSTONE AS OFFICAL TRADING PARTNER
[Picked up by 307 media titles]
2025-01-07 09:00
RuggON Unveils VORTEX Vehicle Mount Computer with AI-Enhanced, SATCOM-Ready
[Picked up by 306 media titles]
2025-01-06 21:00
Brewing Connections and Spotlighting Café Culture: MIFB 2025 Hosts MNCC in Collaboration with MSCA
[Picked up by 305 media titles]
2025-01-06 14:00
iWOW Unveils Age-Tech Innovations at CES 2025, Expanding Portfolio of IoT Solutions for Ageing-In-Place
[Picked up by 291 media titles]
2025-01-07 21:18CELEBRATE THE LUNAR NEW YEAR 2025 AT HOIANA RESORT & GOLF, WORLD'S LEADING FULLY INTEGRATED RESORT
[Picked up by 290 media titles]
2025-01-06 19:25
Most Read
Interest-Driven Consumption Sparks ¥ 500B ACG Goods Market, MINISO Rides the Wave
2025-01-03 19:33
10191
Russell Reynolds Associates Appoints Euan Kenworthy as Singapore Country Manager
2025-01-02 08:16
7930
PieX AI: Launching the World's First Personalized, On-device AI Pendant at CES 2025
2025-01-02 21:00
6113
